• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation.一例载脂蛋白E京都突变型脂蛋白肾小球病的五年随访
CEN Case Rep. 2016 Nov;5(2):148-153. doi: 10.1007/s13730-016-0214-5. Epub 2016 Mar 4.
2
A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports.载脂蛋白 E 赣州突变（Arg43Cys）致脂蛋白肾小球病：两例父子病例报告
J Med Case Rep. 2022 Feb 23;16(1):78. doi: 10.1186/s13256-022-03302-0.
3
Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.载脂蛋白 E 京都突变患者脂蛋白肾小球病的遗传特征、治疗和预后。
Kidney Int. 2014 Feb;85(2):416-24. doi: 10.1038/ki.2013.335. Epub 2013 Sep 11.
4
A young Chinese man with nephrotic syndrome due to lipoprotein glomerulopathy.一位患有脂蛋白肾小球病导致肾病综合征的年轻中国男性。
J Clin Lipidol. 2019 Mar-Apr;13(2):251-253. doi: 10.1016/j.jacl.2018.12.004. Epub 2018 Dec 19.
5
Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.苯扎贝特治疗脂蛋白肾小球病患者时肾小球内脂蛋白血栓消失及肾病综合征明显改善。
Atherosclerosis. 2003 Aug;169(2):293-9. doi: 10.1016/s0021-9150(03)00194-1.
6
Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America.与大阪/仓敷 APOE 变异体相关的脂蛋白肾小球病：在拉丁美洲发现的两例病例。
Diagn Pathol. 2021 Jul 26;16(1):65. doi: 10.1186/s13000-021-01119-x.
7
The Novel Apolipoprotein E Mutation ApoE Chengdu (c.518T＞C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy.载脂蛋白 E 突变 ApoE 成都（c.518T＞C，p.L173P）在中国脂蛋白肾小球病患者中的研究。
J Atheroscler Thromb. 2018 Aug 1;25(8):733-740. doi: 10.5551/jat.41996. Epub 2018 Feb 2.
8
Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report.脂蛋白肾小球病伴明显动脉僵硬，用非诺贝特和氯沙坦联合治疗成功：病例报告。
BMC Nephrol. 2024 May 20;25(1):171. doi: 10.1186/s12882-024-03612-z.
9
A Case of Lipoprotein Glomerulopathy with apoE Chicago and apoE (Glu3Lys) Treated with Fenofibrate.一例伴有载脂蛋白E芝加哥型和载脂蛋白E（谷氨酸3赖氨酸）的脂蛋白肾小球病患者接受非诺贝特治疗的病例。
Case Rep Nephrol Dial. 2017 Jul 27;7(2):112-120. doi: 10.1159/000478902. eCollection 2017 May-Aug.
10
A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.脂蛋白肾小球病中的一种新型载脂蛋白E突变，E2（Arg25Cys）
Kidney Int. 1999 Aug;56(2):421-7. doi: 10.1046/j.1523-1755.1999.00572.x.

引用本文的文献

1
Clinicopathological characteristics and gene mutations in 11 patients with lipoprotein glomerulopathy.脂蛋白肾小球病 11 例患者的临床病理特征及基因突变分析。
Ren Fail. 2024 Dec;46(1):2332491. doi: 10.1080/0886022X.2024.2332491. Epub 2024 Mar 26.
2
Lipoprotein Glomerulopathy, First Case Report from Canada.脂蛋白肾小球病，加拿大首例病例报告。
Int J Nephrol Renovasc Dis. 2022 Jun 21;15:207-214. doi: 10.2147/IJNRD.S364890. eCollection 2022.
3
An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.脂蛋白肾小球病的最新综述与荟萃分析
Front Med (Lausanne). 2022 May 6;9:905007. doi: 10.3389/fmed.2022.905007. eCollection 2022.
4
Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review.脂蛋白肾小球病的发病机制、组织病理学发现及治疗方式：综述
J Bras Nefrol. 2019 Jul-Sep;41(3):393-399. doi: 10.1590/2175-8239-jbn-2018-0148. Epub 2018 Nov 8.

本文引用的文献

1
Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.载脂蛋白 E 京都突变患者脂蛋白肾小球病的遗传特征、治疗和预后。
Kidney Int. 2014 Feb;85(2):416-24. doi: 10.1038/ki.2013.335. Epub 2013 Sep 11.
2
A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy.载脂蛋白 E-Sendai 突变相关脂蛋白肾小球病的一个创始者单倍型。
J Hum Genet. 2013 May;58(5):254-8. doi: 10.1038/jhg.2013.8. Epub 2013 Feb 14.
3
A rare cause of childhood-onset nephrotic syndrome: lipoprotein glomerulopathy.儿童期肾病综合征的罕见病因：脂蛋白肾小球病。
Clin Nephrol. 2012 Sep;78(3):237-40. doi: 10.5414/cn106876.
4
Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities.Fc 受体 γ 缺陷导致的巨噬细胞功能障碍与载脂蛋白 E 异常一起在脂蛋白肾小球病的发生发展中起主要作用。
Nephrol Dial Transplant. 2012 Oct;27(10):3899-907. doi: 10.1093/ndt/gfs329. Epub 2012 Aug 3.
5
A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy.脂蛋白肾小球病患者载脂蛋白 E2 仓敷突变（R158P）。
J Atheroscler Thromb. 2011;18(6):536-41. doi: 10.5551/jat.8102. Epub 2011 Apr 4.
6
Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury.过氧化物酶体增殖物激活受体-α在阿霉素诱导的肾小球损伤中具有肾保护作用。
Kidney Int. 2011 Jun;79(12):1302-11. doi: 10.1038/ki.2011.17. Epub 2011 Mar 2.
7
Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis.非诺贝特是一种过氧化物酶体增殖物激活受体α激动剂，可通过增强肾脏脂解作用发挥肾脏保护作用。
Kidney Int. 2011 Apr;79(8):871-82. doi: 10.1038/ki.2010.530. Epub 2011 Jan 26.
8
Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol.利培酮成功治疗母女的脂蛋白肾小球病。
Clin Exp Nephrol. 2010 Dec;14(6):619-24. doi: 10.1007/s10157-010-0333-9. Epub 2010 Sep 15.
9
Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report.采用低密度脂蛋白吸附术（肝素诱导的体外脂蛋白沉淀系统）治疗脂蛋白肾小球病：一例报告。
J Med Case Rep. 2009 Dec 2;3:9311. doi: 10.1186/1752-1947-3-9311.
10
Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.脂蛋白肾小球病患者强化降脂治疗改善肾病综合征。
Clin Exp Nephrol. 2009 Dec;13(6):659-62. doi: 10.1007/s10157-009-0207-1. Epub 2009 Jul 15.

一例载脂蛋白E京都突变型脂蛋白肾小球病的五年随访

Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation.

作者信息

Usui Ryosuke, Takahashi Masaki, Nitta Kosaku, Koike Minako

机构信息

Division of Nephrology, Department of Medicine, Yachiyo Medical Center, Tokyo Women's Medical University, 477-96, Yachiyo, Chiba, Japan.

Division of Nephrology, Minami-Senju Hospital, Tokyo, Japan.

出版信息

CEN Case Rep. 2016 Nov;5(2):148-153. doi: 10.1007/s13730-016-0214-5. Epub 2016 Mar 4.

DOI:10.1007/s13730-016-0214-5
PMID:28508969
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5411641/
Abstract

We report the case of a 34-year-old Japanese male with lipoprotein glomerulopathy (LPG). Renal biopsy showed LPG, and followed by a genetic analysis revealed a mutation in apolipoprotein E gene (APOE Kyoto; Arg25Cys). We started treatment with probucol, bezafibrate, losartan, and allopurinol. Urinary protein decreased in response to treatment but has remained at about 1.27 ± 0.71 g/gCr, and a repeat biopsy which was performed 1 year after the first biopsy showed no clear evidence of pathological remission and complication of other glomerular disease. After 5 years of follow-up after the start of treatment, renal function has almost maintained without apparent deterioration. Interestingly, the course of the urinary protein level closely paralleled his triglyceride and cholesterol levels in a long-term. This observation suggests the importance of tight control of lipid profiles as a means of renoprotection in LPG patient.

摘要

我们报告了一例34岁的日本男性脂蛋白肾小球病（LPG）患者。肾活检显示为LPG，随后的基因分析发现载脂蛋白E基因（APOE京都型；Arg25Cys）存在突变。我们开始使用普罗布考、苯扎贝特、氯沙坦和别嘌醇进行治疗。治疗后尿蛋白减少，但仍维持在约1.27±0.71 g/gCr，首次活检1年后进行的重复活检未显示明确的病理缓解证据及其他肾小球疾病并发症。治疗开始后随访5年，肾功能几乎维持稳定，无明显恶化。有趣的是，长期来看，尿蛋白水平的变化过程与他的甘油三酯和胆固醇水平密切平行。这一观察结果表明，严格控制血脂水平对于LPG患者肾脏保护具有重要意义。